Metagenomi Therapeutics (MGX) Other financing activities (2025 - 2026)
Metagenomi Therapeutics (MGX) reported Other financing activities of $27000.0 for Q1 2026, down 64.94% year-over-year from $77000.0 in Q1 2025, and up 42.11% quarter-over-quarter from $19000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Other financing activities (2025 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 2 years of Other financing activities data on file, last reported at $27000.0 in Q1 2026.
- Other financing activities for Q1 2026 came in at $27000.0, down 64.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $508000.0 (changed N/A YoY), and the FY2025 annual result was $558000.0, changed N/A from the prior year.
- Other financing activities rose to $27000.0 in Q1 2026 per MGX's latest filing, from $19000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $275000.0 in Q2 2025 and troughed at $19000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 187,000.00 |
| Sep 30, 2025 | 187,000.00 |
| Jun 30, 2025 | 275,000.00 |
| Jun 30, 2025 | 275,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Mar 31, 2025 | 77,000.00 |